COVID-19 vaccine immunity in oncology patients

Hanedan Uslu, Gonca; Yılmaz Rakıcı, Sema; Çopur Çiçek, Ayşegül; Acar Yazıcı, Zihni

COVID-19 vaccine immunity in oncology patients

dc.authorid	0000-0002-3673-9670
dc.contributor.author	Hanedan Uslu, Gonca
dc.contributor.author	Yılmaz Rakıcı, Sema
dc.contributor.author	Çopur Çiçek, Ayşegül
dc.contributor.author	Acar Yazıcı, Zihni
dc.date.accessioned	2023-04-04T08:24:37Z
dc.date.available	2023-04-04T08:24:37Z
dc.date.issued	2023
dc.department	İstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.description.abstract	BACKGROUND: To investigate the effect of vaccine types applied in our country against 2019 coronavirus disease on the formation of protective antibodies in oncology patients. MATERIALS AND METHODS: The data of 81 cancer patients who received at least one dose of vaccine for COVID-19 and radiotherapy were analyzed retrospectively. At any time after the vaccination, blood samples were taken and the antibody titers against the vaccine were measured. RESULTS: There were 28 (34.6 %) patients who received two doses of vaccine and 48 patients (59.3 %) who received 3 doses of vaccine (Sinovac only), while 26 patients (32.1 %) were given both vaccines. The mean time for antibody measurement was 62 days after the last vaccination. IgG levels were significantly higher in patients who received Biontech vaccine than in those who received Sinovac (r = 0.525; p < 0.001). While chemotherapy was the factor that decreased the mean IgM level (p = 0.044), advanced disease (stages 3 and 4) was a significant factor that increased the mean IgG level (p = 0.047). A statistically significant negative correlation was found between IgM antibody level and WBC count after first vaccination (r = ?0.251; p = 0.024). For every WBC count unit increase in the first vaccination period, there was a 1.333-fold increase in the risk of IgM negativity. CONCLUSION: The Biontech vaccine produced higher antibody levels in advanced oncology patients. While the application of radiotherapy in cancer patients was not found to be an effective factor in the vaccination status, it was determined that the application of chemotherapy significantly reduced IgM levels (Tab. 5, Ref. 28). Text in PDF www.elis.sk
dc.description.sponsorship	Recep Tayyip Erdogan University ; Coordination Unit for Projects of Scientific Research	en_US
dc.identifier.citation	Hanedan Uslu, G., Yılmaz Rakıcı, S., Çopur Çiçek, A. ve Acar Yazıcı, Z. (2023). COVID-19 vaccine immunity in oncology patients. Bratislavske Lekarske Listy, 124(3), 187-192. https://dx.doi.org/10.4149/BLL_2023_030
dc.identifier.doi	10.4149/BLL_2023_030
dc.identifier.endpage	192
dc.identifier.issn	0006-9248
dc.identifier.issn	1336-0345
dc.identifier.issue	3
dc.identifier.pmid	36598309
dc.identifier.scopus	2-s2.0-85147834650
dc.identifier.scopusquality	N/A
dc.identifier.startpage	187
dc.identifier.uri	https://dx.doi.org/10.4149/BLL_2023_030
dc.identifier.uri	https://hdl.handle.net/20.500.12511/10796
dc.identifier.volume	124
dc.identifier.wos	000944162900005	en_US
dc.identifier.wosquality	Q4
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	Scopus
dc.indekslendigikaynak	PubMed
dc.institutionauthor	Çopur Çiçek, Ayşegül
dc.language.iso	en
dc.publisher	Aepress Sro
dc.relation.ispartof	Bratislavske Lekarske Listy	en_US
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	COVID-19 Pandemic
dc.subject	COVID-19 Vaccine
dc.subject	Cancer Patients
dc.subject	Radiotherapy
dc.subject	Chemotherapy
dc.subject	SARSCoV-2 IgM and IgG
dc.subject	Abscopal Effect
dc.title	COVID-19 vaccine immunity in oncology patients
dc.type	Article